MAS related GPR family member X6, pseudogeneGenealiases: []
Q-omics provides the consensus-scored MRGPRX6P profile across patient tissues and cancer cell-line models. MRGPRX6P expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, MRGPRX6P is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, MRGPRX6P RNA expression shows 5,584 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight ESCA, BRCA, and COAD as cancer lineages where MRGPRX6P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRGPRX6P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRGPRX6P survival associations across molecular data types. MRGPRX6P RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRGPRX6P RNA expression–survival associations across cancer types. High MRGPRX6P expression shows unfavorable associations in KIRC, LIHC, READ and BLCA, but favorable associations in ESCA and STAD. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify ESCA as the clearest survival context for MRGPRX6P RNA expression.
This table summarizes MRGPRX6P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MRGPRX6P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRGPRX6P shows lower tumor expression in BRCA. The BRCA box plot shows higher MRGPRX6P RNA expression in normal versus tumor tissue (log2 FC = −0.035, t-test p < 0.001).
This table shows molecular features associated with MRGPRX6P in patient tissues and cancer cell lines. In patient samples, MRGPRX6P shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
